KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Progyny (PGNY) Common Equity (2018 - 2025)

Progyny (PGNY) has disclosed Common Equity for 8 consecutive years, with $516.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity changed N/A to $516.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $516.0 million, a N/A change, with the full-year FY2025 number at $516.0 million, changed N/A from a year prior.
  • Common Equity was $516.0 million for Q4 2025 at Progyny, down from $560.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $571.6 million in Q1 2024 to a low of $184.6 million in Q1 2021.
  • A 5-year average of $403.3 million and a median of $434.9 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: surged 78.03% in 2021, then decreased 18.27% in 2025.
  • Progyny's Common Equity stood at $251.8 million in 2021, then surged by 49.7% to $377.0 million in 2022, then surged by 46.81% to $553.4 million in 2023, then decreased by 21.42% to $434.9 million in 2024, then rose by 18.66% to $516.0 million in 2025.
  • Per Business Quant, the three most recent readings for PGNY's Common Equity are $516.0 million (Q4 2025), $560.0 million (Q3 2025), and $515.0 million (Q2 2025).